BioInvent International
28.10.2021 08:31:40 CEST | ACCESS Newswire | Press release
LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV)
"The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio. The integration of functions, on top of world leading science, makes it possible for us to develop novel treatments for patients suffering from serious diseases. The solid balance sheet and strong, loyal shareholders support us in achieving our goals," said Martin Welschof, BioInvent CEO.
Events in the quarter
• (R) BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.
• Emma Meurling joined Bioinvent as Human Resource (HR) Director.
Events after the period
• BioInvent and Transgene announced that preclinical data for BT-001, a novel oncolytic virus delivering an anti-CTLA-4 antibody for the treatment of solid tumors, will be presented at SITC in November 2021.
• New data on the lead drug candidate BI-1206 Phase 1/2a study in non-Hodgkin's lymphoma (NHL) to be presented at the ASH (American Society of Hematology) conference December 11-14.
• New production agreement with CRUK to produce additional batch of anti-HER3 antibody.
• Prof. Eggermont new member of the BioInvent Scientific Advisory Board.
Financial information
Third quarter 2021
• Net sales SEK 3.0 (16.3) million.
• Loss after tax SEK -62.6 (-32.9) million.
• Loss after tax per share before and after dilution SEK -1.07 (-1.00).
• Cash flow from operating activities -57.5 (-31.4) million.
January - September 2021
• Net sales SEK 14.5 (48.6) million.
• Loss after tax SEK -199.7 (-104.9) million.
• Loss after tax per share before and after dilution SEK -3.79 (-4.00).
• Cash flow from operating activities SEK -170.1 (-91.8) million.
• Liquid funds and long-term investments as of September 30, 2021: SEK 1,445.3 (642.1) million.
The complete report is attached as pdf and is available on the company's website www.bioinvent.com/investors/#financialreports.
(R)= Regulatory event
Contacts
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
About Us
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/670065/BioInvent-International-AB-Interim-Report-January--September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
TripGift Launches Its Next-Generation Global Travel Value Platform8.9.2026 14:30:00 CEST | Press release
The 103-currency platform brings together global travel gift cards, rewards, incentives, programmable promotional vouchers and travel redemption across more than 180 countries. NEW YORK CITY, NY / ACCESS Newswire / September 8, 2026 / TripGift, the multi-award-winning global Travel Value Platform, today announced the launch of its next-generation platform, expanding how organizations can integrate travel value into customer, partner and employee programs. Building on TripGift's established global travel gifting and redemption capabilities, the platform brings together its eight proprietary travel gift brands, Travel Value API, Purpose-Bound Promotional Vouchers and travel redemption platform. TripGift's market-leading platform enables travel gift cards to be purchased in 103 currencies and redeemed across more than 180 countries, with access to 2.9 million+ travel and lifestyle booking options, including 2.8 million accommodations, 600 airlines, 30,000 mobility locations, 50,000 tours
A New Force in the Surf Park Economy8.9.2026 13:00:00 CEST | Press release
AWM and China Tourism Group launch Eastern Swell Dynamics SOLANA BEACH, CA / ACCESS Newswire / September 8, 2026 / American Wave Machines is pleased to announce the formation of Eastern Swell Dynamics, a new joint venture established with China Tourism Group to support the growth of PerfectSwell® surf pools across China. The new company will serve as the official licensed platform for PerfectSwell® projects in the region, bringing together AWM's proven surf technology with CTG's deep tourism infrastructure, development capabilities, market access and longstanding presence across Greater China. Riyue Bay Surf Resort powered by PerfectSwell® surf technology China Tourism Group is one of the most significant tourism enterprises in China, with a history dating back more than a century and a business network spanning mainland China, and international markets. Its platform includes travel services, scenic destinations, hotels, duty free retail, tourism transportation, real estate, cultural t
OMP Asia Conferences to Showcase How Industry Leaders Kraft Heinz, Mars, Medac, And Nestlé Approach AI-Powered Supply Chain Planning At "Decision Velocity"8.9.2026 11:35:00 CEST | Press release
Events also feature acclaimed keynote speakers Andrea Iorio, author of "Between You and AI" and former Chief Digital Officer at L'Oréal, and Junjun Gao, a leading voice on supply chain digital transformation in China. SINGAPORE, SG / ACCESS Newswire / September 8, 2026 / OMP, a leading provider of supply chain planning solutions, returns to Asia with two OMP Conferences: Singapore on October 15 and Shanghai on October 20, 2026. Under the theme "Decision velocity," the events bring together supply chain leaders, practitioners, and technology experts to explore how AI-enabled planning helps organizations turn insights into action, respond faster to disruption, and advance toward autonomous planning. The program features customer sessions in Singapore with Nestlé, Kraft Heinz, and Medac, in partnership with PwC, and in Shanghai with Dow and Mars. They will share how they are advancing supply chain planning, strengthening capabilities, and using AI and data to make faster, better decisions
Flow Technology partners with BW Forsyth Partners to Meet Growing Demand for Biopharmaceutical Manufacturing7.9.2026 10:00:00 CEST | Press release
Investment supports Flow Technology's ability to help pharmaceutical and biotechnology manufacturers expand production and navigate increasingly complex manufacturing requirements CHARLEVILLE, IRELAND / ACCESS Newswire / September 7, 2026 / Flow Technology, a provider of engineered process systems and skid integration solutions serving the global life sciences industry, announced a partnership with BW Forsyth Partners that will support the company's continued expansion in the United States and Europe, and enhance its ability to serve the evolving needs of global pharmaceutical and biotechnology manufacturers. The partnership comes as pharmaceutical and biotechnology companies invest heavily in production capacity, advanced manufacturing technologies and domestic supply chains. Flow Technology's expertise in downstream purification, filtration and chromatography systems positions the company to support the increasingly sophisticated process infrastructure required to manufacture next-ge
LiberNovo Showcases Dynamic Ergonomic Seating at IFA 2026 and Supports Special Olympics New York4.9.2026 18:30:00 CEST | Press release
Maxis Series Brings More Space, Support and Choice to Big & Tall Users BERLIN, DE / ACCESS Newswire / September 4, 2026 / LiberNovo is exhibiting at IFA 2026 from September 4 to 8 at Messe Berlin, presenting its dynamic ergonomic seating range at Hall 7, Stand 7.2a-105. The Maxis Series leads the stand, alongside the LiberNovo Omni Pro and Omni SE. LiberNovo Omni Pro has also earned nominations in two IFA Innovation Awards categories: Best in Design and Best in Tech for Good & Accessibility. IFA is a leading event for consumer technology and home appliances, connecting brands, retailers, buyers and media. Its 2026 theme, "The future is now," highlights technology reshaping everyday life. As hybrid work, gaming and content creation extend sitting time, LiberNovo presents seating as an active support system rather than a static object. Maxis Series: Built for Bigger Builds Maxis was designed for taller, broader and heavier users rather than scaled up from a standard chair. Its 52 cm (20.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom